Kura Oncology, Inc. (NASDAQ: KURA) is a Healthcare company (Biotechnology) with a market capitalization of $688M. The Maz Rating grades it against the other companies in its sector.
Kura Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.49, Kura Oncology, Inc. trades at 8.7x sales and 37.4x book value. Over the last twelve months it generated about $79M of revenue and a net loss of $304M. It runs a gross margin of 98.4%, an operating margin of -394.3% and a net margin of -369.3%. It shows return on equity of -336.2%, return on invested capital of -73.0% and a free cash flow yield of -13.0%. On the balance sheet: a debt-to-equity ratio of 1.44 and a current ratio of 3.60. Over the past 52 weeks the share price ranged from $6.75 to $13.90, with a beta of 0.38.
Kura Oncology, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 15 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Kura Oncology, Inc. (KURA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.04% / 30% · (Cash+Inv) / Mkt Cap (36m) 52.7% / 30% · Interest income / Revenue 20.5% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.04% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 52.2% / 33% · Receivables / Mkt Cap (36m) 1.54% / 49% · Interest income / Revenue 20.5% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.04% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 52.2% / 33.33% · Receivables / Mkt Cap (24m) 1.54% / 33.33% · Interest income / Revenue 20.5% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 1.64% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 88.8% / 33.33% · Receivables / Avg Assets (4Q) 1.97% / 33.33% · Interest income / Revenue 20.5% / 5% | Fail |
| FTSE | Debt / Total Assets 1.74% / 33.33% · (Cash+ST Inv) / Total Assets 86.9% / 33.33% · (Cash+Recv) / Total Assets 89.4% / 33.33% · Interest income / Revenue 20.5% / 5% | Fail |
No. As of September 2026, Kura Oncology, Inc. (KURA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Kura Oncology, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 20.5% of each dividend: Kura Oncology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.